Figure 9From: Survivin-responsive conditionally replicating adenovirus kills rhabdomyosarcoma stem cells more efficiently than their progeny The putative therapeutic advantage of m- CRA virotherapy. In general, the therapeutic effectiveness of chemoradiotherapy is decreased in the advanced malignant tumor cells, and in particular, CSCs are resistant to conventional chemoradiotherapies. In contrast, not only m-CRA virotherapy can efficiently kill all populations of malignant tumor cells, including CSCs and their progeny, but also the antitumor effects of m-CRA virotherapy are higher against CSCs.Back to article page